At the 2021 annual congress of the European Society of Medical Oncology (ESMO 2021), South Korea’s Samsung Bioepis has announced five-year follow-up data for On 14 September 2021
With around a week to go until the annual congress of the European Society of Medical Oncology (ESMO), the event already boasts more than 19,000 participants fr 10 September 2021
Combo therapies featuring an immunotherapy and a tyrosine kinase inhibitor (TKI) are all the rage at this year’s annual congress of the European Society of Medi 21 September 2020
Chinese biopharma Innovent Biologics and US drugmaker Eli Lilly have jointly announced that biomarker results from the ORIENT-11 study were released in a mini o 21 September 2020
The Johnson & Johnson unit Janssen has announced interim results from the CHRYSALIS study, evaluating amivantamab in combination with the third-generation EGFR 21 September 2020
A late-breaking paper discussed at the annual congress of ESMO 2020 shows positive data for an investigational antibody-drug conjugate (ADC) developed by Seattl 21 September 2020
Impressive data for another immuno-oncology / tyrosine kinase inhibitor (TKI) combo add up to yet more competition in the first-line kidney cancer setting. 21 September 2020
Eli Lilly’s Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 21 September 2020
Swiss drugmaker Roche has presented detailed results from the Phase III IMpassion031 study of Tecentriq (atezolizumab), at the European Society for Medical Onco 21 September 2020
A new immuno-oncology combination from Bristol Myers Squibb (NYSE: BMY) and Exelixis (Nasdaq: EXEL) could make a real difference in kidney cancer, the firms out 19 September 2020
Updated results from the PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained.clinically meaningful overall survival (OS) 18 September 2020
French pharma major Sanofi has announced positive results from the pivotal Phase II trial for the PD-1 inhibitor Libtayo (cemiplimab) in locally advanced basal 18 September 2020
Data presented at the 2020 annual congress of the European Society of Medical Oncology (ESMO) show long-term progression-free survival (PFS) benefit versus plac 18 September 2020
At the annual congress of the European Society of Medical Oncology (ESMO), taking place virtually, Johnson & Johnson’s pharma arm Janssen hopes to raise the bar 17 September 2020
Despite a range of online resources to facilitate interactions between attendees, there clearly won’t be the same opportunities for networking at this year’s an 15 September 2020
At this year’s annual congress of the European Society of Medical Oncology (ESMO), taking place virtually, there is a strong focus on evaluating the impact of t 14 September 2020
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.